The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase

Andrea Kassai, László Illyés, Hossein Z. Mirdamadi, I. Seres, Tímea Kalmár, Mária Audikovszky, G. Paragh

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objectives: The aim of our study was to examine the influence of atorvastatin on lipid parameters, particularly on HDL, and on the activity of LCAT and CETP and how they affect the activity of the HDL-associated antioxidant enzyme paraoxonase. Design and methods: Thirty-three patients with types II.a and II.b primary hyperlipoproteinemia were enrolled into our study. The patients received atorvastatin, 20 mg daily, for 3 months. We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. Results: Atorvastatin significantly reduced the levels of cholesterol, triglyceride, LDL-C and apoB, while it did not influence the levels of HDL-C and apo A-I. The increases in serum PON-specific activity, PON/HDL ratio and LCAT activity were significant, while oxLDL and CETP activities were significantly decreased. Conclusion: Atorvastatin may influence the composition and function of HDL, thereby possibly increasing the activity of paraoxonase and preventing atherosclerosis.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalClinical Biochemistry
Volume40
Issue number1-2
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Cholesterol Ester Transfer Proteins
Phosphatidylcholine-Sterol O-Acyltransferase
Aryldialkylphosphatase
Antioxidants
Hyperlipoproteinemias
Apolipoprotein A-I
Apolipoproteins B
Therapeutics
Serum
LDL Cholesterol
Atherosclerosis
Cholesterol
Lipids
Atorvastatin Calcium
Enzymes
Chemical analysis
oxidized low density lipoprotein

Keywords

  • Atorvastatin
  • Cholesteryl ester transfer protein (CETP)
  • High-density lipoprotein (HDL)
  • Lecithin:cholesterol acyltransferase (LCAT)
  • Paraoxonase (PON)

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The effect of atorvastatin therapy on lecithin : cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. / Kassai, Andrea; Illyés, László; Mirdamadi, Hossein Z.; Seres, I.; Kalmár, Tímea; Audikovszky, Mária; Paragh, G.

In: Clinical Biochemistry, Vol. 40, No. 1-2, 01.2007, p. 1-5.

Research output: Contribution to journalArticle

Kassai, Andrea ; Illyés, László ; Mirdamadi, Hossein Z. ; Seres, I. ; Kalmár, Tímea ; Audikovszky, Mária ; Paragh, G. / The effect of atorvastatin therapy on lecithin : cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. In: Clinical Biochemistry. 2007 ; Vol. 40, No. 1-2. pp. 1-5.
@article{746d87ff69c24538ad7c837180c85663,
title = "The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase",
abstract = "Objectives: The aim of our study was to examine the influence of atorvastatin on lipid parameters, particularly on HDL, and on the activity of LCAT and CETP and how they affect the activity of the HDL-associated antioxidant enzyme paraoxonase. Design and methods: Thirty-three patients with types II.a and II.b primary hyperlipoproteinemia were enrolled into our study. The patients received atorvastatin, 20 mg daily, for 3 months. We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. Results: Atorvastatin significantly reduced the levels of cholesterol, triglyceride, LDL-C and apoB, while it did not influence the levels of HDL-C and apo A-I. The increases in serum PON-specific activity, PON/HDL ratio and LCAT activity were significant, while oxLDL and CETP activities were significantly decreased. Conclusion: Atorvastatin may influence the composition and function of HDL, thereby possibly increasing the activity of paraoxonase and preventing atherosclerosis.",
keywords = "Atorvastatin, Cholesteryl ester transfer protein (CETP), High-density lipoprotein (HDL), Lecithin:cholesterol acyltransferase (LCAT), Paraoxonase (PON)",
author = "Andrea Kassai and L{\'a}szl{\'o} Illy{\'e}s and Mirdamadi, {Hossein Z.} and I. Seres and T{\'i}mea Kalm{\'a}r and M{\'a}ria Audikovszky and G. Paragh",
year = "2007",
month = "1",
doi = "10.1016/j.clinbiochem.2006.05.016",
language = "English",
volume = "40",
pages = "1--5",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - The effect of atorvastatin therapy on lecithin

T2 - cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase

AU - Kassai, Andrea

AU - Illyés, László

AU - Mirdamadi, Hossein Z.

AU - Seres, I.

AU - Kalmár, Tímea

AU - Audikovszky, Mária

AU - Paragh, G.

PY - 2007/1

Y1 - 2007/1

N2 - Objectives: The aim of our study was to examine the influence of atorvastatin on lipid parameters, particularly on HDL, and on the activity of LCAT and CETP and how they affect the activity of the HDL-associated antioxidant enzyme paraoxonase. Design and methods: Thirty-three patients with types II.a and II.b primary hyperlipoproteinemia were enrolled into our study. The patients received atorvastatin, 20 mg daily, for 3 months. We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. Results: Atorvastatin significantly reduced the levels of cholesterol, triglyceride, LDL-C and apoB, while it did not influence the levels of HDL-C and apo A-I. The increases in serum PON-specific activity, PON/HDL ratio and LCAT activity were significant, while oxLDL and CETP activities were significantly decreased. Conclusion: Atorvastatin may influence the composition and function of HDL, thereby possibly increasing the activity of paraoxonase and preventing atherosclerosis.

AB - Objectives: The aim of our study was to examine the influence of atorvastatin on lipid parameters, particularly on HDL, and on the activity of LCAT and CETP and how they affect the activity of the HDL-associated antioxidant enzyme paraoxonase. Design and methods: Thirty-three patients with types II.a and II.b primary hyperlipoproteinemia were enrolled into our study. The patients received atorvastatin, 20 mg daily, for 3 months. We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. Results: Atorvastatin significantly reduced the levels of cholesterol, triglyceride, LDL-C and apoB, while it did not influence the levels of HDL-C and apo A-I. The increases in serum PON-specific activity, PON/HDL ratio and LCAT activity were significant, while oxLDL and CETP activities were significantly decreased. Conclusion: Atorvastatin may influence the composition and function of HDL, thereby possibly increasing the activity of paraoxonase and preventing atherosclerosis.

KW - Atorvastatin

KW - Cholesteryl ester transfer protein (CETP)

KW - High-density lipoprotein (HDL)

KW - Lecithin:cholesterol acyltransferase (LCAT)

KW - Paraoxonase (PON)

UR - http://www.scopus.com/inward/record.url?scp=33845797118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845797118&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2006.05.016

DO - 10.1016/j.clinbiochem.2006.05.016

M3 - Article

C2 - 16999950

AN - SCOPUS:33845797118

VL - 40

SP - 1

EP - 5

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 1-2

ER -